Protein tyrosine phosphatase, non-receptor type 11 (SHP2)

Protein tyrosine phosphatase, non-receptor type 11 (SHP2) is a ubiquitously expressed enzyme encoded by the PTPN11 gene. It contains two N-terminal Src homology 2 (SH2) domains and a catalytic protein tyrosine phosphatase (PTP) domain, enabling it to regulate a variety of intracellular signaling pathways. SHP2 is crucial for positive signal transduction downstream of receptor and cytoplasmic tyrosine kinases, functioning as a key regulator of the RAS/MAPK pathway, and thus influences cell growth, differentiation, migration, and survival. Pathogenic mutations in PTPN11/SHP2 are linked to developmental syndromes (notably Noonan and LEOPARD syndromes) and play a significant role in oncogenesis through sustained oncogenic signaling. Dysregulation—whether by mutation or aberrant expression—can promote cancer, making SHP2 an important target for small-molecule inhibitors currently under clinical investigation for cancer and other diseases. Its broad physiological importance, however, poses safety and therapeutic challenges[1][4][6].

Other names

SHP2PTPN11Protein tyrosine phosphatase, non-receptor type 11Src homology 2 domain-containing phosphatase-2

Inhibition of SHP2 phosphatase activity (often allosteric inhibition to maintain SHP2 in an auto-inhibited conformation) Disruption of SHP2-mediated signal transduction (esp. RAS/MAPK pathway) Reduction of downstream cell proliferation and survival signals